Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Angiogenesis and Antibodies

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5246
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Angiogenesis and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Angiogenesis and Antibodies.

    To find out more about Triple Analysis: Melanoma, Angiogenesis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Angiogenesis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
3SBio
A&G Pharmaceutical
AB Science
Abbott
AbbVie
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actelion
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agennix
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Alnylam
AlphaVax
ALSP
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Amphora
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Bayer
Berkeley Lab
Bio-Medisinsk Innovasjon
BioAlliance Pharma
BioAxone
Biocad
Biocon
Biogen Idec
BioInvent
Biokine Therapeutics
Biolex
BioLineRx
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cosmo Pharmaceuticals
CSL
Cue Biotech
CuraGen
CureTech
Curis
Customized Therapeutics
Cyclacel
CytImmune Sciences
Cytochroma
Cytokinetics
Daewoong
Daiichi Sankyo
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
DNAVEC
Dompe
Dong-A
Dr Reddy’s
Dyax
Eisai
Elan
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Ergon Pharmaceuticals
EUSA Pharma
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Flamel Technologies
Fusion Antibodies
Galaxy Biotech
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Genta
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
Gradalis
Green Cross
Hawthorn Pharmaceuticals
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inotek
Inovio
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Kaketsuken
KaloBios
Kalypsys
Karus Therapeutics
Karyon-CTT
Kiadis
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Kyto Biopharma
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
MAT Biopharma
Meda
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Morvus Technology
Mycenax
Neovacs
Nereus Pharmaceuticals
Neuren
NewSouth Innovations
NIH
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
Novelix
Novogen
Noxxon
Oasmia
Oncalis
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
Panacea
PanGenetics
Patrys
PBL Therapeutics
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacopeia
PharmaMar
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
Protein Sciences
Protgen
PTC Therapeutics
Ramot
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sareum
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Shanghai CP Guojian
Shenogen
Shionogi
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spear Therapeutics
Spirogen
SRI International
Stainwei Biotech
Sunesis
Sunol Molecular
SuperGen
SuppreMol
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
SynerGene Therapeutics
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
to-BBB
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
VBL Therapeutics
Vectura
Vical
Wilex
VioQuest
Viragen
Viventia Biotech
WntResearch
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
YM BioSciences
York Pharma
Zenotech
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
ABT-510
adecatumumab
AEB071
aflibercept
agatolimod
AGS-1C4D4
ALD-518
aldesleukin
alemtuzumab
ALT-801
amatuximab
AME-133
AMG-386
Angiozyme
apatinib
APO-866
ARQ-197
ARRY-438162
astuprotimut-r
atrasentan
Auto TAG vaccine
AV-299
axitinib
bardoxolone methyl
belimumab
belinostat
bevacizumab
BHQ880
BIBF-1120
blinatumomab
BMS-663513
BMS-690514
BMS-936558
bortezomib
brentuximab vedotin
brivanib alaninate
BT-062
Buparlisib
Cabozantinib
carlumab
catumaxomab
CB-10-01
CDX-1307
CDX-1401
cediranib
cetuximab
cilengitide
cixutumumab
CMAB302
CMAB304
conatumumab
cositecan
CT-011
dalotuzumab
daratumumab
dasatinib
decitabine
denenicokin
denileukin diftitox
denosumab
DI-17E6
dinaciclib
dovitinib lactate
E-7820
E7449
elotuzumab
EMD-273063
EMD525797
endostatin
ENMD-2076
entinostat
enzastaurin hydrochloride
epirubicin
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
foretinib
fosbretabulin tromethamine
fresolimumab
galiximab
ganetespib
ganitumab
gefitinib
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GliaAtak
golvatinib
GS-6634
GSK-1120212
GSK-2118436
GT-111
GV-1001
GVAX
HBP-347
Hi-8 MEL
histamine dihydrochloride
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
imatinib mesilate
INCB-24360
inotuzumab ozogamicin
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
IPH-2102
ipilimumab
IPP-204106
iratumumab
ispinesib mesylate
JI-101
JX-594
kahalalide F
L19-IL2
L19-TNFalpha
Lambrolizumab
LEE-011
lenvatinib
LGX818
linifanib
lintuzumab
LIP-131I
LipoVIL12
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY-2275796
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDX-1379
MEDI-551
MEDI-573
MetXia
MGCD-265
MGN-1601
midostaurin
milatuzumab
milatuzumab-doxorubicin
MKC-1106-MT
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
motesanib diphosphate
moxetumomab pasudotox
muparfostat (IV)
naptumomab estafenatox
natalizumab
necitumumab
NGR-TNF
nilotinib
nimotuzumab
obinutuzumab
ofatumumab
olaratumab
ON-01910
onartuzumab
OncoVAX
Onyvax-105
oregovomab
OTS-102
P276-00
paclitaxel
PancAtak
panitumumab
PAT-SC1
pazopanib hydrochloride
PCI-27483
pegdinetanib
peginterferon alfa-2b
perifosine
pertuzumab
PF-4856884
pimasertib
plitidepsin
poly-ICLC
ponatinib
ProstAtak
PTC-299
RAF-265
ramucirumab
Reditux
regorafenib
retaspimycin
RG-7160
rhIFN-alpha
ridaforolimus
rilotumumab
rintatolimod
rituximab
robatumumab
romiplostim
sagopilone
samalizumab
SAR-3419
sargramostim
SCIB-1
selumetinib
siltuximab
sirolimus
sorafenib tosylate
sotatercept
SU-6668
sunitinib malate
Sym-004
talactoferrin alfa
talminogene laherparepvec
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
tesetaxel
thalidomide
thymalfasin
tigatuzumab
tipifarnib
tivozanib
tocilizumab
trabedersen
TRC-105
tremelimumab
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
vandetanib
velimogene aliplasmid
veliparib
veltuzumab
vemurafenib
verubulin
vinflunine ditartrate
vismodegib
vitespen
volociximab
XL-184
XL-647
YM-155
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Angiogenesis and Antibodies.
    To find out more about Triple Analysis: Melanoma, Angiogenesis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Angiogenesis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Lung Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Breast Cancer, Leukemia and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Pancreatic Cancer. Learn More

Other selected research from the 'Oncology' category:


Target Atlas in Bone Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Triple Analysis: Breast Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More